On May 26, 2023, the Minister of Health determined that Biosimilar Collaborations Ireland Limited was entitled to the benefit of section 5 of the Patented Medicines (Notice of.
The 12th edition of the U.S. Chamber’s International IP Index is a comprehensive assessment of the world’s intellectual property frameworks. It shows the power of smart policies to foster innovation, creativity, and economic growth and unlock opportunity.
On December 23, 2023, the Federal Court of Appeal (FCA) held that it was an abuse of process for Apotex to raise invalidity in defending actions under the Patented Medicines (Notice of.
In a patent infringement action brought by Allergan and AbbVie under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (Regulations), in relation to 0.01% w/v.
On December 4, 2023, the Federal Court issued its public judgment and reasons in two patent infringement actions pursuant to s. 6(1) of the Patented Medicines (Notice of Compliance).
Federal Court of Appeal (FCA) dismisses appeal on finding of inducement: Apotex Inc v Janssen Inc, 2023 FCA 220 - Apotex appealed the trial decision, finding that.
The Patented Medicines Prices Review Board (PMPRB) has launched the first phase of consultations on its new Guidelines, inviting feedback through upcoming policy roundtables.
On May 26, 2023, the Minister of Health issued a decision that Biosimilar Collaborations Ireland Limited (BCIL) was entitled to the benefit of a notice of allegation (NOA) served by the.
As previously reported, the Patented Medicine Prices Review Board (PMPRB) proposed amendments in June 2023 to its Interim Guidance (“Amended Interim Guidance”) for reviewing the prices.